Reuters logo
BRIEF-Intellia Therapeutics provides more data on CRISPR technology
March 8, 2017 / 1:25 PM / 9 months ago

BRIEF-Intellia Therapeutics provides more data on CRISPR technology

March 8 (Reuters) - Intellia Therapeutics Inc

* Intellia therapeutics- updated data showing increased levels of genome editing efficiency in vivo and durability results with its crispr/cas9 technology

* Intellia therapeutics- first to demonstrate single dose, in vivo results, showing about 97 percent reduction in serum transthyretin protein levels

* Intellia therapeutics inc - durability data show stable liver editing for at least four months

* Intellia therapeutics inc - increased liver editing efficiency reported to date at 70 percent, following a single dose Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below